What Kyverna Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 2 |
| Sells | 0 | 1 |
| Total trades | 0 | 16 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 473,349 |
| Disposed | 0 | 28,192 |
| Net activity | +0 | +445,157 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Aktar Mert | Director | May 27 | Grant / award · A | +5,093 | — | — | 21,727 |
| Shaw Christi | Executive Chairperson | May 27 | Withheld — tax / exercise cost · F | −4,194 | $8.59 | −$36K | 66,741 |
| Seidenberg Beth C | Director | May 27 | Grant / award · A | +5,093 | — | — | 21,727 |
| Cohen Fred E | Director | May 27 | Grant / award · A | +5,093 | — | — | 21,727 |
| Clark Ian T | Director | May 27 | Grant / award · A | +5,093 | — | — | 21,727 |
| Grasso Marc | Chief Financial Officer | Mar 13 | Grant / award · A | +10,000 | — | — | 10,000 |
| Biddle Warner Weston | Chief Executive Officer | Mar 13 | Grant / award · A | +58,000 | — | — | 58,000 |
| Gehchan Naji | See Remarks | Mar 13 | Grant / award · A | +18,000 | — | — | 18,000 |
| Miller Andrew Craig | Director | Feb 24 | Grant / award · A | +11,006 | — | — | 11,006 |
| Emany Sravan Kumar | Director | Feb 24 | Grant / award · A | +11,006 | — | — | 11,006 |
| Shaw Christi | Executive Chairperson | Jan 12 | Grant / award · A | +24,301 | — | — | 70,935 |
| Shaw Christi | Executive Chairperson | Jan 12 | Grant / award · A | +30,000 | — | — | 46,634 |
| Westlake BioPartners Opportunity Fund I, L.p. | 10% owner | Dec 18 | Open-market buy · P | +133,333 | $7.50 | +$1M | 869,317 |
| Seidenberg Beth C | Director | Dec 18 | Open-market buy · P | +133,333 | $7.50 | +$1M | 869,317 |
| Walker Karen Marie | Chief Technology Officer | Dec 15 | Disclosed 10b5-1 sale · S | −23,998 | $12.20 | −$293K | 22,636 |
| Walker Karen Marie | Chief Technology Officer | Dec 15 | Exercise / conversion · M | +23,998 | $4.83 | +$116K | 46,634 |
| Cohen Fred E | Director | May 29 | Grant / award · A | +16,634 | — | — | 16,634 |
| Aktar Mert | Director | May 29 | Grant / award · A | +16,634 | — | — | 16,634 |
| Spiegelman Daniel K | Director | May 29 | Grant / award · A | +16,634 | — | — | 16,634 |
| Seidenberg Beth C | Director | May 29 | Grant / award · A | +16,634 | — | — | 16,634 |
Loading...